Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
Peter Alagona JrPenn State Heart and Vascular Institute, Penn State College of Medicine, Hershey, PA, USAAbstract: The last two to three decades have seen an explosive growth in interest and information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence for the role of lo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/fenofibric-acid-a-new-fibrate-approved-for-use-in-combination-with-sta-a4433 |
| _version_ | 1811248996212015104 |
|---|---|
| author | Peter Alagona Jr |
| author_facet | Peter Alagona Jr |
| author_sort | Peter Alagona Jr |
| collection | DOAJ |
| description | Peter Alagona JrPenn State Heart and Vascular Institute, Penn State College of Medicine, Hershey, PA, USAAbstract: The last two to three decades have seen an explosive growth in interest and information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence for the role of low-density lipoprotein (LDL) in risk has led to a series of clinical guidelines/recommendations on the importance of LDL lowering with statin treatment. There is also substantial evidence on a number of lipoproteins in the initiation and progression of atherosclerosis and CV events. Health care professionals have not embraced easily novel approaches to identifying those at increased risk and more aggressive treatment. This is especially true for non-LDL factors. The use of non-statin drugs such as fibrates has been modest and many health care professionals avoid consideration of combination therapy due to an inordinate fear of toxicity. This review will attempt to provide appropriate background information on lipids/lipoproteins, including non-high density lipoprotein and risk, as well as data available on fibrates and combination pharmacologic therapy. We will review a new agent, TriLipix® (fenofibric acid), and its potential role in treatment.Keywords: dyslipidemia, peroxisome proliferated activated receptors, fibrate, fenofibric acid, TriLipix, very-low-density lipoprotein, triglycerides, non-high density lipoprotein |
| first_indexed | 2024-04-12T15:38:41Z |
| format | Article |
| id | doaj.art-4e6fa787aee5479fb0ef9217639c3a57 |
| institution | Directory Open Access Journal |
| issn | 1176-6344 1178-2048 |
| language | English |
| last_indexed | 2024-04-12T15:38:41Z |
| publishDate | 2010-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-4e6fa787aee5479fb0ef9217639c3a572022-12-22T03:26:52ZengDove Medical PressVascular Health and Risk Management1176-63441178-20482010-05-012010default351362Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemiaPeter Alagona JrPeter Alagona JrPenn State Heart and Vascular Institute, Penn State College of Medicine, Hershey, PA, USAAbstract: The last two to three decades have seen an explosive growth in interest and information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence for the role of low-density lipoprotein (LDL) in risk has led to a series of clinical guidelines/recommendations on the importance of LDL lowering with statin treatment. There is also substantial evidence on a number of lipoproteins in the initiation and progression of atherosclerosis and CV events. Health care professionals have not embraced easily novel approaches to identifying those at increased risk and more aggressive treatment. This is especially true for non-LDL factors. The use of non-statin drugs such as fibrates has been modest and many health care professionals avoid consideration of combination therapy due to an inordinate fear of toxicity. This review will attempt to provide appropriate background information on lipids/lipoproteins, including non-high density lipoprotein and risk, as well as data available on fibrates and combination pharmacologic therapy. We will review a new agent, TriLipix® (fenofibric acid), and its potential role in treatment.Keywords: dyslipidemia, peroxisome proliferated activated receptors, fibrate, fenofibric acid, TriLipix, very-low-density lipoprotein, triglycerides, non-high density lipoproteinhttp://www.dovepress.com/fenofibric-acid-a-new-fibrate-approved-for-use-in-combination-with-sta-a4433 |
| spellingShingle | Peter Alagona Jr Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia Vascular Health and Risk Management |
| title | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| title_full | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| title_fullStr | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| title_full_unstemmed | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| title_short | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| title_sort | fenofibric acid a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| url | http://www.dovepress.com/fenofibric-acid-a-new-fibrate-approved-for-use-in-combination-with-sta-a4433 |
| work_keys_str_mv | AT peteralagonajr fenofibricacidanewfibrateapprovedforuseincombinationwithstatinforthetreatmentofmixeddyslipidemia |